Shanghai Fosun Pharmaceutical Group Co Ltd

Shanghai Fosun Pharmaceutical Group Co Ltd has a capital structure with 540,971,500 basic and diluted shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. The liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company's profitability and returns are not currently available for comparison against industry_config preferred metrics or cohort medians, as the valuation snapshot does not provide relevant ratios such as ROIC or margins. This lack of data limits the ability to assess its performance relative to industry peers.

Segment and geographic exposure data are not disclosed in the available financial snapshot, making it difficult to evaluate revenue concentration or geographic diversification. Without segment-specific revenue breakdowns, the company's exposure to different markets or product lines remains opaque.

Growth trajectory data is also not available, as the outlook for the current and next fiscal years does not include numeric deltas or revenue history. This absence of forward-looking guidance or historical performance metrics hinders the ability to assess the company's growth potential.

The risk assessment indicates a low dilution potential, with no significant dilution sources identified in the available documents. However, the liquidity risk remains unassessed due to the lack of balance-sheet inputs and no going-concern language in source documents.

Recent events, such as filings or transcripts, are not disclosed in the available data, limiting the ability to assess the company's recent strategic or operational developments.

Revenue ¥41.50B, +1,4% YoY; Operating income +15,9% YoY.

• ▍Revenue ¥41.50B, +1,4% YoY
• ▍Operating income +15,9% YoY
• ▍Net income +21,7% YoY
• ▍Free cash flow +71,2% YoY
• ▍Net margin 8.1%

Revenue ¥40.91B, −0,8% YoY; Operating income +74,6% YoY.

• ▍Revenue ¥40.91B, −0,8% YoY
• ▍Operating income +74,6% YoY
• ▍Net income +15,5% YoY
• ▍Free cash flow +496,3% YoY
• ▍Net margin 6.8%

Revenue ¥41.25B, −5,8% YoY; Operating income −40,1% YoY.

• ▍Revenue ¥41.25B, −5,8% YoY
• ▍Operating income −40,1% YoY
• ▍Net income −35,8% YoY
• ▍Free cash flow +55,6% YoY
• ▍Net margin 5.8%

Revenue ¥43.81B, +12,7% YoY; Operating income −29,2% YoY.

• ▍Revenue ¥43.81B, +12,7% YoY
• ▍Operating income −29,2% YoY
• ▍Net income −21,0% YoY
• ▍Free cash flow −206,1% YoY
• ▍Net margin 8.5%

Revenue ¥38.86B; Operating income ¥4.84B.

• ▍Revenue ¥38.86B
• ▍Operating income ¥4.84B
• ▍Net margin 12.2%